<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440424</url>
  </required_header>
  <id_info>
    <org_study_id>E2006-A001-104</org_study_id>
    <nct_id>NCT03440424</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects</brief_title>
  <official_title>An Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to assess the effect of mild and moderate hepatic impairment on
      the pharmacokinetics (PK) of lemborexant after a single-dose administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Anticipated">April 17, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of lemborexant</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under plasma concentration versus time curve from time = 0 to time of last quantifiable concentration (AUC [0-t]) of lemborexant</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under plasma concentration versus time curve from time = 0 to infinity (AUC[0-inf]) of lemborexant</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time to reach maximum plasma concentration (Tmax) of lemborexant and its metabolites</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean terminal plasma phase half-life (t½) of lemborexant and its metabolites</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent total body clearance (CL/F) of lemborexant</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent volume of distribution (Vz/F) of lemborexant</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Metabolite Ratio</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
    <description>The AUC metabolite ratio is the ratio of AUC(0-inf) of the individual metabolite to AUC(0-inf) of lemborexant, corrected for molecular weights.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein unbound fraction (fu) of lemborexant and its metabolites</measure>
    <time_frame>Blood samples will be obtained at 1 and 24 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC(0-inf) values adjusted by unbound fraction in plasma (AUCu) of lemborexant</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent clearance relative to the unbound plasma concentration based on AUCu (CLu/F) of lemborexant</measure>
    <time_frame>Blood samples will be obtained at predose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (Day 1); 24 (Day 2); 48 (Day 3); 72 (Day 4); 96 (Day 5); 120 (Day 6); 144 (Day 7); 168 (Day 8); 216 (Day 10); 264 (Day 12); and 312 (Day 14) hours postdose.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Cohort A: Mild Hepatic Impairment (Child Pugh Class A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Healthy Participants (Control)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants matched to participants in Cohorts A and B will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lemborexant</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Cohort A: Mild Hepatic Impairment (Child Pugh Class A)</arm_group_label>
    <arm_group_label>Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)</arm_group_label>
    <arm_group_label>Cohort C: Healthy Participants (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria for All Participants:

          -  Male or female participants, ages 18 to 79, inclusive, at the time of informed consent

          -  Body Mass Index (BMI) between 18 and 40 kilograms per meters squared, inclusive, at
             Screening

          -  Voluntary agreement to provide written informed consent, and the willingness and
             ability to comply with all aspects of the protocol

          -  Nonsmokers or smokers who smoke 20 cigarettes or less per day

          -  For Cohorts A and B: stable (without any change in disease status for at least 60 days
             prior to study Screening) hepatic impairment conforming to Child-Pugh classification A
             or B, respectively, and documented by medical history and a physical examination

          -  For Cohort C: healthy participants matched to participants with hepatic impairment
             with regard to age (±10 years), sex, and BMI (±20%), and as determined by no
             clinically significant deviation from normal in medical history, physical examination,
             electrocardiogram (ECG), and clinical laboratory determinations

        Exclusion Criteria:

        Exclusion Criteria for All Participants:

          -  Females who are breastfeeding or pregnant at Screening or Baseline

          -  Females of childbearing potential. Note: All females will be considered to be of
             childbearing potential unless they are postmenopausal (amenorrheic for at least 12
             consecutive months, in the appropriate age group, and without other known or suspected
             cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total
             hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before
             dosing).

          -  Known to be positive for human immunodeficiency virus

          -  Currently enrolled in another clinical study or used any investigational drug or
             device within 4 weeks, or 5 times the half-life of the investigational drug (whichever
             is longer), preceding informed consent

          -  Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or
             donation of plasma within 1 week of dosing until study discharge

          -  Intake of herbal preparations containing St. John's Wort within 4 weeks prior to
             dosing until study discharge

          -  Intake of nutritional supplements (including herbal preparations), foods or beverages
             that may affect cytochrome P3A enzyme (e.g., alcohol, grapefruit, grapefruit juice,
             grapefruit-containing beverages, apple or orange juice, vegetables from the mustard
             green family [e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels
             sprouts, mustard] and charbroiled meats) within 1 week before dosing until study
             discharge

          -  Intake of beverages, food, or other products that contain caffeine from 24 hours
             before until 48 hours after dosing with lemborexant

          -  Engagement in strenuous exercise (e.g., moving large bulky items, bodybuilding) within
             2 weeks prior to check-in until study discharge

          -  History of clinically significant drug or food allergies, or is presently experiencing
             significant seasonal allergies

          -  A prolonged QT/corrected QT (QTc) interval (QTc &gt;480 milliseconds) demonstrated on ECG
             at Screening or Baseline (Day -1)

          -  Any major surgery within 4 weeks of study drug administration

          -  Any history of abdominal surgery that may affect pharmacokinetics of lemborexant
             (e.g., hepatectomy, nephrectomy, digestive organ resection)

          -  Inability to tolerate oral medication

          -  Inability to tolerate venous access and/or venipuncture

          -  Unwilling to abide by the study requirements, or in the opinion of the investigator,
             is not likely to complete the study

        Additional Exclusion Criteria for Hepatically Impaired Participants (Cohorts A and B):

        In addition to the Exclusion Criteria listed above for all participants, other standard
        exclusion criteria for participants with hepatic impairment will be used. These include:

          -  Any significant acute medical illness (such as new conditions or exacerbation of
             pre-existing conditions) within 8 weeks of dosing

          -  Medical conditions which are not adequately and stably controlled on stable doses of
             medications or which, in the clinical opinion of the Principal Investigator, may
             interfere with study procedures or participant safety within 4 weeks before dosing
             (e.g., psychiatric disorders and disorders of the gastrointestinal tract, kidney,
             respiratory system, endocrine system, hematological system, neurological system, or
             cardiovascular system, or participants who have a congenital abnormality in
             metabolism)

          -  History of esophageal and gastric variceal bleeding within the past 6 months unless
             the participant has completed a course of endoscopic therapy with the appropriate
             documentation (e.g., endoscopy report) of successful ablation of esophageal varices;
             participants with esophageal varices may be included if not bleeding within the past 6
             months or have been treated adequately by ablation therapy, as specified above.

          -  Spontaneous bacterial peritonitis within 3 months of dosing

          -  Treatment with plasmapheresis within 6 months of dosing

          -  Primarily cholestatic liver diseases (e.g., primary biliary cirrhosis or primary
             sclerosing cholangitis)

          -  Current or recent (within 3 months prior to Screening) history of significant
             gastrointestinal disease other than that secondary to hepatic impairment

          -  Autoimmune liver disease

          -  Active alcoholic hepatitis determined either clinically or by histology

          -  History of hepatoma or metastatic disease of the liver

          -  Presence of severe ascites or edema

          -  Presence of hepatopulmonary syndrome or hydrothorax, or hepatorenal syndrome

          -  Known significant bleeding diathesis that could preclude multiple venipunctures
             (international normalization ratio &gt;2.5)

          -  Creatinine clearance &lt;60 milliliters per minute at Screening or Baseline as calculated
             using Cockroft and Gault Equation

          -  The participant's standard therapy/concomitant medication for diseases related to
             cirrhosis has not remained stable/unchanged for at least 14 days before the first dose
             of study drug

          -  History of drug or alcohol dependency or abuse within 4 weeks prior to Screening, or
             those who have a positive urine drug test or breath alcohol test at Screening or
             Baseline unless a prescribed medication for the underlying condition is the cause of
             the positive urine screen

        Additional Exclusion Criteria for Healthy Participants (Cohort C):

        In addition to the Exclusion Criteria listed above for all participants, other standard
        exclusion criteria for healthy participants in Phase 1 studies will be used. These include:

          -  Presence of active liver disease, or acute liver injury, as indicated by (1) an
             abnormal liver function test, or (2) clinical or laboratory signs of active viral
             hepatitis (including B and C, as demonstrated by positive serology at Screening)

          -  Clinically significant illness, within 4 weeks prior to dosing, that requires medical
             treatment or may influence the outcome of the study; e.g., psychiatric disorders and
             disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine
             system, hematological system, neurological system, or cardiovascular system, or
             participants who have a congenital abnormality in metabolism

          -  Any abnormal finding based on physical examination, assessment of vital signs, ECG, or
             laboratory test results that require treatment or clinical follow-up based on the
             investigator's opinion

          -  History of drug or alcohol use disorder within the 2 years prior to Screening, or
             those who have a positive urine drug test or breathalyzer alcohol test at Screening or
             Baseline

          -  Use of any prescription drugs within 4 weeks prior to dosing until study discharge

          -  Intake of any over-the-counter medications within 2 weeks prior to dosing until study
             discharge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>1-888-274-2378</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild hepatic impairment</keyword>
  <keyword>moderate hepatic impairment</keyword>
  <keyword>lemborexant</keyword>
  <keyword>healthy participants</keyword>
  <keyword>metabolites</keyword>
  <keyword>E2006</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

